Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701186 | 0.90 | EPHX2 (0.38) | EPHX2CHRM2CHRM4CHRM3NR1H2 | |
| SCHEMBL13738558 | 0.84 | CHRNB2 (0.50) | EPHX2NR1H2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL14296568 | 0.80 | CYP3A4 (0.31) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL9972960 | 0.80 | CHRM2 (0.35) | CHRM2CHRM4CHRM3NR1H2CHRNB2 | |
| SCHEMBL7234329 | 0.79 | CHRM2 (0.39) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL2966759 | 0.79 | — | — | |
| SCHEMBL17592505 | 0.79 | — | — | |
| SCHEMBL2966762 | 0.79 | — | — | |
| SCHEMBL2955470 | 0.79 | — | — | |
| SCHEMBL2127138 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | SLC10A2, SLC10A1, SLC5A11 | EPHX2 2584/4885CHRM2 2915/4885CHRM4 4068/4885 |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | SLC10A2, SLC10A1, SLC5A11 | EPHX2 2584/4885CHRM2 2915/4885CHRM4 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.